Table 4.
Summary of phase 3 study for hepatitis C virus-human immunodeficiency virus co-infected patients
| Genotype | Study name | Population | Treatment | Duration (wk) | n | LC (%) | SVR12 (%) |
| 1 | PHOTON-1 | Naïve | SOF/RBV | 12 | 114 | 4.4 | 76 |
| PHOTON-2 | Naïve | SOF/RBV | 24 | 112 | 15 | 85 | |
| 2 | PHOTON-1 | Naïve | SOF/RBV | 12 | 26 | - | 88 |
| Experienced | SOF/RBV | 24 | 24 | - | 92 | ||
| PHOTON-2 | Naïve | SOF/RBV | 12 | 19 | 5 | 89 | |
| Experienced | SOF/RBV | 24 | 6 | 33 | 83 | ||
| 3 | PHOTON-1 | Naïve | SOF/RBV | 12 | 42 | - | 67 |
| Experienced | SOF/RBV | 24 | 17 | - | 94 | ||
| PHOTON-2 | Naïve | SOF/RBV | 24 | 57 | 5 | 91 | |
| Experienced | SOF/RBV | 24 | 49 | 47 | 86 | ||
| 4 | PHOTON-2 | Naïve | SOF/RBV | 24 | 31 | 26 | 84 |
LC: Liver cirrhosis; SVR12: Sustained virologic response at 12 wk; Naïve: Treatment-naïve; Experienced: Treatment-experienced; SOF: Sofosbuvir; IFN: Interferon; RBV: Ribavirin.